(Adnkronos) - “Come gruppo Menarini siamo orgogliosi di aver contribuito a sviluppare e a portare a disposizione delle pazienti italiane questa nuova terapia elacestrant. Oggi, grazie al nostro impegno, abbiamo dato la possibilità a 100 donne” con cancro al seno “di accedere a questo trattamento”. Lo ha detto il General manager di Menarini Stemline Italia, Nicola Bencini, intervenendo a un corso di aggiornamento sul carcinoma mammario Er+/Her2 - avanzato o metastatico con mutazioni Esr1, che si è tenuto a Roma
Category
🗞
NewsTranscript
00:00As Menarini Group, we are proud to have contributed to develop and make available to the Italian patients this therapeutic innovation.
00:17We are in the setting of the metastatic hormonoresponsive cancer disease, an innovation that in the field of monohormone therapies was not seen for more than 20 years.
00:29Today, thanks to the commitment of the Menarini Group, through a compassionate use program, we have given the opportunity to access this therapy in a few months to more than 100 patients and others will have access to it in the coming weeks.
00:48We are referring to a subgroup of patients that are characterized by an SR1 mutation that has, as the publications report, a prognostic value, clearly unfavorable compared to the rest of the patients,
01:09but also a predictive value in response to this new class of drugs, of which Elacestran is a first-in-class.
01:17Once again, we are proud as an Italian company to have contributed in this sense to bring an innovation that was not present.
01:28We clearly do not stop there, but the commitment of the group is to continue to develop new molecules, both in the mammary carcinoma but also in other solid types, in addition to the commitment that we also have in hematology for several months.